RE:RE:RE:Immunomodulating theranostic PDC for melanomaHi bencro;
Your mighty effort to bring continued valuable information to the board is greatly appreciated by many here, myself included. You have my heart felt thank you.
The issue that troubles me and I been more outspoken of lately, is the fact that Theralase is not playing the media game at all. They are not arranging interviews for Roger to bring in new interest.
I must now say the words that should not be spoken. “Your work, and the NR’s are mostly read by the folks here, and few others.” That just is not going to move the share price and give Roger the option of a fair or overheated share price to conduct a PP or a bought deal.
Roger is left with the option of conducting small PP’s and a slow bleed, You know that we are so much better than that.
I have been investing for many decades and I have never seen a company with so much potential, yet so shy to promote itself to new blood using the already public information.
bencro, you are a very bright individual, I would be most interested in your thoughts about the lack of promotion, and why such a stance is sensible when we keep ourselves in the difficult position to continually raise capital in order to move this company forward.
Thank you in advance, I await your response;
made2last
bencro wrote: Dr. McFarland's Ir(III) PDC would be for the melanoma cancer
Dr. McFarland's July 2017 paper on a 3rd family of PDC (Iridium) would seem to target the
melanoma cancer indication.
Still some work to do though.
Near-infrared-emitting heteroleptic cationic iridium complexes derived from 2,3-diphenylbenzo[g]quinoxaline as in vitro theranostic photodynamic therapy agents - Dalton Transactions ... While the photophysics of these complexes differ slightly, their theranostic photodynamic therapy (PDT) effects varied drastically. All of the complexes were biologically active toward melanoma cells. Complexes 2 and 3 were the most cytotoxic, with 230–340 nM activity and selectivity factors for melanoma cells over normal skin fibroblasts of 34 to 40 fold. Complexes 2, 3, and 5 became very potent cytotoxins with light activation, with EC50 values as low as 12–18 nM. This potent nanomolar light-triggered activity combined with a lower dark toxicity resulted in 5 having a phototherapeutic index (PI) margin of almost 275. ________________
bencro - (11/4/2017 3:04:55 PM) RE:Immunomodulating theranostic PDC for melanoma Interesting ... She also lectured on the same subject at another university, back in April 2016 ... So her work must be more advanced than we can think of.
MUN Chemistry - Seminars - Adventures in Photomedicine: Using Light-Mediated Processes to Improve Health and Treat Disease - Dr. Sherri McFarland ____________________________________
bencro - (11/4/2017 12:28:31 PM) Immunomodulating theranostic PDC for melanoma ProOrbite ... Amazing catch. Thanks for sharing.
This adds to the 2013 paper of Dr. McFarland on melanoma:
Exploitation of Long-Lived 3IL Excited States for Metal–Organic Photodynamic Therapy: Verification in a Metastatic Melanoma Model _____________________________
Adventures in Photomedicine: Using Light-Mediated Processes to Improve Health and Treat Disease - Dr. Sherri McFarland Adventures in Photomedicine: Using Light-Mediated Processes to Improve Health and Treat Disease
Dr. Sherri McFarland,
Acadia University
April 14th, 2017 – Spring Seminar
Time and location: Noon at Chem 120
Host: Dr. Lisa Kelly
Adventures in Photomedicine: Using Light-Mediated Processes to Improve Health and Treat Disease
Photomedicine is an interdisciplinary field where chemistry and light meet to fight disease. Photodynamic therapy (PDT) is a special branch of photomedicine that employs a sensitizer molecule, light, and oxygen to destroy target cells with spatiotemporal selectivity. Despite its enormous potential for treating certain diseases, including cancer and infection, PDT has yet to become mainstream. Over the past 10 years, my group has addressed key issues that have hampered bench-to-bedside progress in the field of PDT. Using a multidisciplinary approach, we have introduced both synthetic compounds and natural products (both currently being investigated in human clinical trials) as alternatives to existing porphyrin-based PDT agents for specific indications. This seminar will share some of our past experiences in developing metallodrug photosensitizers for treating bladder cancer (and photoactive plant extracts for improving oral health if time permits), and will highlight new directions toward the design of immunomodulating theranostic photosensitizers for melanoma PDT.